Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry

N/AWithdrawnNCT00212511

NYU Langone Health

Overview

The purpose of this study is to create a database of demographics and samples in idiopathic pulmonary fibrosis.

Study Type

OBSERVATIONAL

Conditions

Idiopathic Pulmonary Fibrosis

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria 1. Male or Female greater or equal to age 18. 2. Referral by physician with the diagnosis of IPF, or interstitial lung disease (IPF considered likely). Exclusion Criteria (a) Unwilling or unable to give written informed consent.

Locations (1)

NYU School of Medicine

New York, New York, United States

Outcomes

Primary Outcomes

Determine cellular and molecular determinants of IPF

An IPF Registry is being established to assemble sufficient patients with IPF (especially in its earliest stage) for phase I therapeutic protocols. The Registry will incorporate demographic and clinical data for natural history studies; second, research data on physiology, high-resolution CT scan, questionnaires, and blood samples for blood banking to be collected every 6 months for prospective studies on pathophysiology; and third, response to standard therapies will be monitored to determine cellular and molecular relationships to clinical outcome and predictors of survival. This is done in order to better determine cellular and molecular determinants of IPF. This cohort will be large enough to commence a separate phase I protocol with molecular strategies of intervention.

Time frame: Long-Term

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.